Dr. Sven Kili is a respected KOL in healthcare and biotechnology, boasting over 20 years of experience. He began as a surgeon in the NHS, where he gained valuable insights into patient care. Transitioning to Cell and Gene Therapies (CGT), Sven played key roles in leading the development, approval and commercialization of both a cell therapy and the first ex-vivo gene therapy. With expertise across all stages of CGT development, he has built companies and teams in both large pharma/ biotech and startups. Sven is a partner at Saisei Ventures, a boutique therapeutic venture investment firm focussed on creating and growing innovative companies, including with a focus on the Japanese CGT ecosystem. He also heads his consulting firm, Sven Kili Consulting Ltd., oQering strategic guidance to organizations in the biotech and healthcare sectors. Most recently he served as the Chief Development OQicer for CCRM (Centre for Commercialization of Regenerative Medicine) and OmniaBio. Sven actively contributes to industry boards and committees, including the BIA CGTAC, Innovation Hubs for Gene Therapy, ISCT, and ARM. Sven holds a visiting chair at UCL (University College London), where he heads the steering committee for a post-grad degree in Cell & Gene Therapy manufacturing and commercialisation. His dedication to advancing regenerative medicine and CGT is reflected in his multifaceted roles and ongoing eQorts to shape the future of healthcare through innovation and strategic collaboration